ICON Public (NASDAQ:ICLR) Updates FY 2025 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 13.000-15.000 for the period, compared to the consensus estimate of 14.200. The company issued revenue guidance of $8.1 billion-$8.7 billion, compared to the consensus revenue estimate of $8.4 billion.

ICON Public Stock Down 0.7 %

Shares of NASDAQ:ICLR opened at $185.18 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a 1 year low of $179.50 and a 1 year high of $347.72. The stock has a market capitalization of $14.95 billion, a P/E ratio of 19.43, a PEG ratio of 1.86 and a beta of 1.21. The stock has a 50-day simple moving average of $200.24 and a 200-day simple moving average of $237.92.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Equities analysts forecast that ICON Public will post 13.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ICLR. JPMorgan Chase & Co. reduced their target price on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Robert W. Baird reduced their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday. Leerink Partners reiterated an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Finally, Truist Financial cut their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.